Why Vir Biotechnology Inc’s (VIR) Stock Is Down 5.22% (2024)

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vir Biotechnology Inc before investing.

In this article, we go over a few key elements for understanding Vir Biotechnology Inc’s stock price such as:

Before we jump into Vir Biotechnology Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Want to learn more about Vir Biotechnology Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vir Biotechnology Inc.

As of June 11, 2024, 4:00 PM, CST, Vir Biotechnology Inc’s stock price was $10.63.

Vir Biotechnology Inc is down 5.22% from its previous closing price of $11.21.

During the last market session, Vir Biotechnology Inc’s stock traded between $10.49 and $11.22. Currently, there are 135.28 million shares of Vir Biotechnology Inc stock available for purchase.

Unfortunately, Vir Biotechnology Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Vir Biotechnology Inc’s (VIR) price is currently up 3.46% so far this month.

During the month of June, Vir Biotechnology Inc’s stock price has reached a high of $13.09 and a low of $10.38.

Over the last year, Vir Biotechnology Inc has hit prices as high as $27.48 and as low as $7.61. Year to date, Vir Biotechnology Inc’s stock is down 58.02%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2024, there were 0 analysts who downgraded Vir Biotechnology Inc’s stock and 6 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Vir Biotechnology Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vir Biotechnology Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Vir Biotechnology Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vir Biotechnology Inc (VIR) by visiting AAII Stock Evaluator.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2024, Vir Biotechnology Inc has a weighted four-quarter relative price strength of -14.28%, which translates to a Momentum Score of 25 and is considered to be Weak.

Want to learn more about how Vir Biotechnology Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

As of June 11, 2024, Vir Biotechnology Inc’s stock price is $10.63, which is down 5.22% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vir Biotechnology Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.